Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB01136,Carvedilol
,26348083,50% inhibitory concentration (IC(50)),Cilostazol inhibited CYP2C9 activity in a concentration-dependent manner with 50% inhibitory concentration (IC(50)) of 8.7 μM.,Effects of cilostazol on the pharmacokinetics of carvedilol after oral and intravenous administration in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26348083/),μM,8.7,1794,DB01136,Carvedilol
,20515526,flow rate,The eluent was monitored by spectroflourimetric detector at a flow rate of 1.0 mL/min.,High-performance liquid chromatography determination of carvedilol in pig serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515526/),[ml] / [min],1.0,3794,DB01136,Carvedilol
more,20515526,recovery,"The intra-day and inter-day coefficient of variation and percent error values of the assay method were less than 15%, and mean recovery was more than 89.95 and 94.27 for carvedilol and IS, respectively.",High-performance liquid chromatography determination of carvedilol in pig serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515526/),,89.95,3795,DB01136,Carvedilol
more,20515526,recovery,"The intra-day and inter-day coefficient of variation and percent error values of the assay method were less than 15%, and mean recovery was more than 89.95 and 94.27 for carvedilol and IS, respectively.",High-performance liquid chromatography determination of carvedilol in pig serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20515526/),,94.27,3796,DB01136,Carvedilol
,26743643,systemic availability,"Carvedilol, a beta-adrenergic blocker, suffers from poor systemic availability (25%) due to first-pass metabolism.","Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26743643/),%,25,14281,DB01136,Carvedilol
,26743643,EE%,The results revealed high drug EE% ranging from 68 to 87.62%.,"Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26743643/),%,68 to 87.62,14282,DB01136,Carvedilol
,26743643,absolute bioavailability,The in vivo pharmacokinetic study revealed that the absolute bioavailability of the optimized intranasal SLNs (50.63%) was significantly higher than oral carvedilol formulation (24.11%).,"Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26743643/),%,50.63,14283,DB01136,Carvedilol
,26743643,absolute bioavailability,The in vivo pharmacokinetic study revealed that the absolute bioavailability of the optimized intranasal SLNs (50.63%) was significantly higher than oral carvedilol formulation (24.11%).,"Development, Optimization, and Evaluation of Carvedilol-Loaded Solid Lipid Nanoparticles for Intranasal Drug Delivery. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26743643/),%,24.11,14284,DB01136,Carvedilol
,25463209,flow rate,The analysis was performed in less than 6 min with a flow rate of 0.4 mL/min.,Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463209/),[ml] / [min],0.4,14525,DB01136,Carvedilol
>,25463209,recoveries,Assay recoveries were high (>91%) and internal standard normalized matrix effects were minimal.,Simultaneous quantification of carvedilol and its metabolites in rat plasma by ultra performance liquid chromatography tandem mass spectrometry and pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25463209/),%,91,14526,DB01136,Carvedilol
,34089041,flow rate,Chromatography was performed on Thermo Hypersil C18 column using mobile phase comprising of ACN: 10 mM KH2PO4 (51.2:48.8) with 1 mL min-1 flow rate and detection wavelength was fixed at 210 nm.,Multiresponse Optimization of HPLC Method: Simultaneous Estimation of Protease Inhibitors and NNRTI in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089041/),[ml] / [min],1,16286,DB01136,Carvedilol
,34089041,analysis time,The analysis time was within 9 min.,Multiresponse Optimization of HPLC Method: Simultaneous Estimation of Protease Inhibitors and NNRTI in Human Plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34089041/),min,9,16287,DB01136,Carvedilol
,23010056,globule size,The optimized formulation (mean globule size: 40.8 nm) indicated marked improvement in drug release profile vis-à-vis pure drug and marketed formulation.,Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23010056/),nm,40.8,20653,DB01136,Carvedilol
,23010056,C(max),Augmentation in the values of C(max) (134.2%) and AUC (85.2%) indicated significant enhancement in the rate and extent of bioavailability by the S-SNEDDS formulation compared to pure drug.,Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23010056/),%,134.2,20654,DB01136,Carvedilol
,2454364,elimination half-life,The elimination half-life after single oral doses varies from 6-7 h.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),h,6-7,24549,DB01136,Carvedilol
,2454364,renal clearance,The renal clearance of 4 ml/min is negligible in comparison with the total body clearance of 590 ml/min.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),[ml] / [min],4,24550,DB01136,Carvedilol
,2454364,total body clearance,The renal clearance of 4 ml/min is negligible in comparison with the total body clearance of 590 ml/min.,A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),[ml] / [min],590,24551,DB01136,Carvedilol
,2454364,absolute bioavailability,"Therefore, the absolute bioavailability of 24% indicates some degree of first-pass extraction.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),%,24,24552,DB01136,Carvedilol
,2454364,distribution volume,"The highly lipophilic drug is extensively distributed to the tissues, as shown by the distribution volume of 132 l.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),l,132,24553,DB01136,Carvedilol
,2454364,responder rate,"In a 1-year open clinical trial with hypertensives WHO I and II, the responder rate was about 85% with carvedilol as monotherapy.",A new molecule with vasodilating and beta-adrenoceptor blocking properties. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454364/),%,85,24554,DB01136,Carvedilol
,32416685,absolute bioavailability,"After oral administration, CD is rapidly absorbed with an absolute bioavailability of 18-25% because of low solubility and extensive first-pass metabolism.",In-situ Intestinal Absorption and Pharmacokinetic Investigations of Carvedilol Loaded Supersaturated Self-emulsifying Drug System. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32416685/),%,18-25,25147,DB01136,Carvedilol
,26651381,Particle size,Particle size of Car-NS was found to be 183 ± 2.43 nm with an entrapment efficiency of 81.4 ± 0.512%.,Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651381/),nm,183,25920,DB01136,Carvedilol
,26651381,entrapment efficiency,Particle size of Car-NS was found to be 183 ± 2.43 nm with an entrapment efficiency of 81.4 ± 0.512%.,Fabrication of novel GMO/Eudragit E100 nanostructures for enhancing oral bioavailability of carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26651381/),%,81.4,25921,DB01136,Carvedilol
not exceed,25834396,absolute bioavailability,"Due to its lower aqueous solubility and extensive first-pass metabolism, the absolute bioavailability of CVD does not exceed 30%.",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),%,30,29997,DB01136,Carvedilol
,25834396,solubility,The solubility of CVD was improved from 7.32 to 22.92 mg/mL after complexation with hydroxypropyl-β-cyclodextrin at a molar ratio of 1:2 (CVD to cyclodextrin).,Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),[mg] / [ml],7.32,29998,DB01136,Carvedilol
,25834396,solubility,The solubility of CVD was improved from 7.32 to 22.92 mg/mL after complexation with hydroxypropyl-β-cyclodextrin at a molar ratio of 1:2 (CVD to cyclodextrin).,Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),[mg] / [ml],22.92,29999,DB01136,Carvedilol
,25834396,disintegration time,"The formulated CVD-ODTs showed satisfactory results concerning tablet hardness (5.35 kg/cm(2)), disintegration time (18 seconds), and maximum amount of CVD released (99.72%).",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),seconds,18,30000,DB01136,Carvedilol
,25834396,maximum amount,"The formulated CVD-ODTs showed satisfactory results concerning tablet hardness (5.35 kg/cm(2)), disintegration time (18 seconds), and maximum amount of CVD released (99.72%).",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),%,99.72,30001,DB01136,Carvedilol
,25834396,maximum plasma concentration,"The pharmacokinetic data for the optimized CVD-ODT showed a significant (P<0.05) increase in maximum plasma concentration from 363.667 to 496.4 ng/mL, and a shortening of the time taken to reach maximum plasma concentration to 2 hours in comparison with the marketed tablet.",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),[ng] / [ml],363.667,30002,DB01136,Carvedilol
,25834396,maximum plasma concentration,"The pharmacokinetic data for the optimized CVD-ODT showed a significant (P<0.05) increase in maximum plasma concentration from 363.667 to 496.4 ng/mL, and a shortening of the time taken to reach maximum plasma concentration to 2 hours in comparison with the marketed tablet.",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),[ng] / [ml],496.4,30003,DB01136,Carvedilol
,25834396,time taken to reach maximum plasma concentration,"The pharmacokinetic data for the optimized CVD-ODT showed a significant (P<0.05) increase in maximum plasma concentration from 363.667 to 496.4 ng/mL, and a shortening of the time taken to reach maximum plasma concentration to 2 hours in comparison with the marketed tablet.",Development and optimization of carvedilol orodispersible tablets: enhancement of pharmacokinetic parameters in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25834396/),h,2,30004,DB01136,Carvedilol
,22246736,zeta potential,The optimized formulation showed a mean size of 212 ± 12 nm and a zeta potential of -42 ± 3 mV.,Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22246736/),m,-42,33001,DB01136,Carvedilol
,7914479,elimination half-life,It reaches a peak concentration 1 to 2 hours postdose and has an elimination half-life of about 4 to 7 hours.,Clinical pharmacokinetics and pharmacodynamics of carvedilol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914479/),h,4 to 7,34853,DB01136,Carvedilol
,16005691,chromatographic run time,The method had a chromatographic run time of 3.5 min and a linear calibration curve over the range 0.1-200 ng ml(-1) (r2>0.997992).,Quantification of carvedilol in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry: application to bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16005691/),min,3.5,46192,DB01136,Carvedilol
,31353479,plasma exposure,Carvedilol pharmacokinetics (data presented as median) were enantioselective with higher plasma exposure of (R)-(+)-carvedilol in both control (103.5 vs 46.0 ng ∙ h/mL) and CKD (190.6 vs 98.9 ng ∙ h/mL) groups.,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],103.5,50147,DB01136,Carvedilol
,31353479,plasma exposure,Carvedilol pharmacokinetics (data presented as median) were enantioselective with higher plasma exposure of (R)-(+)-carvedilol in both control (103.5 vs 46.0 ng ∙ h/mL) and CKD (190.6 vs 98.9 ng ∙ h/mL) groups.,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],46.0,50148,DB01136,Carvedilol
,31353479,plasma exposure,Carvedilol pharmacokinetics (data presented as median) were enantioselective with higher plasma exposure of (R)-(+)-carvedilol in both control (103.5 vs 46.0 ng ∙ h/mL) and CKD (190.6 vs 98.9 ng ∙ h/mL) groups.,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],190.6,50149,DB01136,Carvedilol
,31353479,plasma exposure,Carvedilol pharmacokinetics (data presented as median) were enantioselective with higher plasma exposure of (R)-(+)-carvedilol in both control (103.5 vs 46.0 ng ∙ h/mL) and CKD (190.6 vs 98.9 ng ∙ h/mL) groups.,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],98.9,50150,DB01136,Carvedilol
,31353479,area under the plasma concentration-time curve,Lercanidipine increased the area under the plasma concentration-time curve of only (R)-(+)-carvedilol in the CKD group (190.6 vs 242.2 ng ∙ h/mL) but not in the control group (103.5 vs 98.7 ng ∙ h/mL).,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],190.6,50151,DB01136,Carvedilol
,31353479,area under the plasma concentration-time curve,Lercanidipine increased the area under the plasma concentration-time curve of only (R)-(+)-carvedilol in the CKD group (190.6 vs 242.2 ng ∙ h/mL) but not in the control group (103.5 vs 98.7 ng ∙ h/mL).,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],242.2,50152,DB01136,Carvedilol
,31353479,area under the plasma concentration-time curve,Lercanidipine increased the area under the plasma concentration-time curve of only (R)-(+)-carvedilol in the CKD group (190.6 vs 242.2 ng ∙ h/mL) but not in the control group (103.5 vs 98.7 ng ∙ h/mL).,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],103.5,50153,DB01136,Carvedilol
,31353479,area under the plasma concentration-time curve,Lercanidipine increased the area under the plasma concentration-time curve of only (R)-(+)-carvedilol in the CKD group (190.6 vs 242.2 ng ∙ h/mL) but not in the control group (103.5 vs 98.7 ng ∙ h/mL).,Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],98.7,50154,DB01136,Carvedilol
,31353479,plasma exposure,"CKD increased plasma exposure (46.0 vs 98.9 ng ∙ h/mL) and effect-compartment exposure (5.5 vs 20.9 ng ∙ h/mL) to (S)-(-)-carvedilol, resulting in higher β-adrenergic inhibition (10.0 vs 6.1 bpm).",Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],46.0,50155,DB01136,Carvedilol
,31353479,plasma exposure,"CKD increased plasma exposure (46.0 vs 98.9 ng ∙ h/mL) and effect-compartment exposure (5.5 vs 20.9 ng ∙ h/mL) to (S)-(-)-carvedilol, resulting in higher β-adrenergic inhibition (10.0 vs 6.1 bpm).",Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],98.9,50156,DB01136,Carvedilol
,31353479,effect-compartment exposure,"CKD increased plasma exposure (46.0 vs 98.9 ng ∙ h/mL) and effect-compartment exposure (5.5 vs 20.9 ng ∙ h/mL) to (S)-(-)-carvedilol, resulting in higher β-adrenergic inhibition (10.0 vs 6.1 bpm).",Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],5.5,50157,DB01136,Carvedilol
,31353479,effect-compartment exposure,"CKD increased plasma exposure (46.0 vs 98.9 ng ∙ h/mL) and effect-compartment exposure (5.5 vs 20.9 ng ∙ h/mL) to (S)-(-)-carvedilol, resulting in higher β-adrenergic inhibition (10.0 vs 6.1 bpm).",Effect of Lercanidipine on the Pharmacokinetics-Pharmacodynamics of Carvedilol Enantiomers in Patients With Chronic Kidney Disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31353479/),[h·ng·∙] / [ml],20.9,50158,DB01136,Carvedilol
,17995971,weight-adjusted clearance,The weight-adjusted clearance was highest for the younger patients with 2.7 l h(-1) kg(-1) for a 1-year-old patient compared with 0.7 l h(-1) kg(-1) for a 19.3-year-old patient.,Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17995971/),[l] / [h·kg],2.7,50161,DB01136,Carvedilol
,17995971,weight-adjusted clearance,The weight-adjusted clearance was highest for the younger patients with 2.7 l h(-1) kg(-1) for a 1-year-old patient compared with 0.7 l h(-1) kg(-1) for a 19.3-year-old patient.,Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17995971/),[l] / [h·kg],0.7,50162,DB01136,Carvedilol
,10630779,elimination half-life,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,54,50507,DB01136,Carvedilol
,10630779,half-life of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),min,3.5,50508,DB01136,Carvedilol
,10630779,volume of distribution,"Mean elimination half-life was 54 minutes, half-life of distribution was 3.5 minutes, and volume of distribution was 2,038 ml/kg.",Acute cardiovascular effects and pharmacokinetics of carvedilol in healthy dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10630779/),[ml] / [kg],"2,038",50509,DB01136,Carvedilol
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,33,50838,DB01136,Carvedilol
,17910813,bioavailability,Co-administration with carvedilol increased ciclosporin bioavailability from 33% to 70%.,Carvedilol increases ciclosporin bioavailability by inhibiting P-glycoprotein-mediated transport. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17910813/),%,70,50839,DB01136,Carvedilol
,32275957,relative bioavailability,"Moreover, a 1.56-fold increase in the relative bioavailability of CAR was observed for the CAR PI-SNEDDS (397.41%) compared to a CAR SNEDDS (254.09%) with commercial capsules as a reference.",A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32275957/),%,397.41,55787,DB01136,Carvedilol
,32275957,relative bioavailability,"Moreover, a 1.56-fold increase in the relative bioavailability of CAR was observed for the CAR PI-SNEDDS (397.41%) compared to a CAR SNEDDS (254.09%) with commercial capsules as a reference.",A Soluplus/Poloxamer 407-based self-nanoemulsifying drug delivery system for the weakly basic drug carvedilol to improve its bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32275957/),%,254.09,55788,DB01136,Carvedilol
,16415527,serum concentration to dose (C/D ratio),"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],47.8,56048,DB01136,Carvedilol
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],47.8,56049,DB01136,Carvedilol
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],95.3,56050,DB01136,Carvedilol
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],0.460,56051,DB01136,Carvedilol
,16415527,C/D ratio,"There was no significant between-group difference of the serum concentration to dose (C/D ratio) for the R-enantiomer carvedilol, however, the C/D ratio for the S-enantiomer and the serum S-carvedilol to R-carvedilol (S/R) ratio were both significantly lower in the carvedilol group than in the carvedilol+amiodarone group(47.8+/-56.7 versus 95.3+/-105 ng/mg/kg, P=0.0048 and 0.460+/-0.207 versus 0.879+/-0.377 ng/mg/kg, P<0.001), respectively.",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [kg·mg],0.879,56052,DB01136,Carvedilol
,16415527,concentration,"Furthermore, the mean S-carvedilol concentration over 14 days of coadministration with amiodarone was higher than that before coadministration (6.54+/-1.73 ng/mL versus 3.03+/-0.670 ng/mL, P<0.001).",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [ml],6.54,56053,DB01136,Carvedilol
,16415527,concentration,"Furthermore, the mean S-carvedilol concentration over 14 days of coadministration with amiodarone was higher than that before coadministration (6.54+/-1.73 ng/mL versus 3.03+/-0.670 ng/mL, P<0.001).",Stereoselective effect of amiodarone on the pharmacokinetics of racemic carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415527/),[ng] / [ml],3.03,56054,DB01136,Carvedilol
,1586585,Vdss,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),[l] / [kg],3.32,58335,DB01136,Carvedilol
,1586585,Vdss,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),[l] / [kg],2.21,58336,DB01136,Carvedilol
,1586585,MRT,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),min,33.4,58337,DB01136,Carvedilol
,1586585,MRT,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),min,25.6,58338,DB01136,Carvedilol
,1586585,CLtot,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),[ml] / [kg·min],96.1,58339,DB01136,Carvedilol
,1586585,CLtot,"As compared with the (+)-(R), the (-)-(S) had a larger Vdss (3.32 vs. 2.21 liter/kg), MRT (33.4 vs. 25.6 min), and CLtot (96.1 vs. 83.8 ml/min/kg).",Stereoselective disposition and tissue distribution of carvedilol enantiomers in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1586585/),[ml] / [kg·min],83.8,58340,DB01136,Carvedilol
,26251598,relative bioavailability,"The relative bioavailability of F2 and F5 formulations to the suspension was estimated to be 1.84 and 1.64, respectively.",Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26251598/),,1.84,63035,DB01136,Carvedilol
,26251598,relative bioavailability,"The relative bioavailability of F2 and F5 formulations to the suspension was estimated to be 1.84 and 1.64, respectively.",Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26251598/),,1.64,63036,DB01136,Carvedilol
,12040358,Elimination half-life,Elimination half-life was about 50% shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P <.05).,Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040358/),h,2.9,65256,DB01136,Carvedilol
,12040358,Elimination half-life,Elimination half-life was about 50% shorter in pediatric CHF patients compared with healthy adult volunteers (2.9 vs 5.2 hours; P <.05).,Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12040358/),h,5.2,65257,DB01136,Carvedilol
,22132944,IC50,"Myricetin inhibited CYP2C9 and CYP2D6 enzyme activity with IC50 of 13 and 57 μM, respectively.",Effects of myricetin on the bioavailability of carvedilol in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22132944/),μM,13,67439,DB01136,Carvedilol
,22132944,IC50,"Myricetin inhibited CYP2C9 and CYP2D6 enzyme activity with IC50 of 13 and 57 μM, respectively.",Effects of myricetin on the bioavailability of carvedilol in rats. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22132944/),μM,57,67440,DB01136,Carvedilol
,2454374,half-life,Calculation of the half-life of carvedilol gave values of 2.2 to 9 h.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),h,2.2 to 9,83799,DB01136,Carvedilol
,2454374,volume of distribution,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [kg],1.54,83800,DB01136,Carvedilol
,2454374,total body clearance,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [h·kg],0.521,83801,DB01136,Carvedilol
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],4004.37,89017,DB01136,Carvedilol
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],1824.30,89018,DB01136,Carvedilol
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],753.46,89019,DB01136,Carvedilol
,20382272,AUC((0)(-)(t)),"A significant improvement in bioavailability was observed with the transdermal patches over oral tablets as observed by the mean AUC((0)(-)(t)) values 4004.37+/-180.98 and 1824.30+/-17.43ngh/mL respectively for CRV and HCTZ as compared to 753.46+/-53.34 and 392.89+/-34.23ngh/mL respectively, with the oral tablets.","Randomised, cross-over, comparative bioavailability trial of matrix type transdermal drug delivery system (TDDS) of carvedilol and hydrochlorothiazide combination in healthy human volunteers: a pilot study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20382272/),[ngh] / [ml],392.89,89020,DB01136,Carvedilol
,1974498,absolute bioavailability,"Following p.o. administration, the absolute bioavailability (31.1% and 15.1%, respectively) and maximal plasma concentrations of R(+)-CARV were twice those of S(-)-CARV.",Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974498/),%,31.1,91658,DB01136,Carvedilol
,1974498,absolute bioavailability,"Following p.o. administration, the absolute bioavailability (31.1% and 15.1%, respectively) and maximal plasma concentrations of R(+)-CARV were twice those of S(-)-CARV.",Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1974498/),%,15.1,91659,DB01136,Carvedilol
,16379664,peak concentration,"The median peak concentration (extrapolated) of carvedilol after IV administration was 476 ng/mL (range, 203 to 1,920 ng/mL), elimination half-life (t(1/2)) was 282 minutes (range, 19 to 1,021 minutes), and mean residence time (MRT) was 360 minutes (range, 19 to 819 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),[ng] / [ml],476,98939,DB01136,Carvedilol
,16379664,elimination half-life (t(1/2)),"The median peak concentration (extrapolated) of carvedilol after IV administration was 476 ng/mL (range, 203 to 1,920 ng/mL), elimination half-life (t(1/2)) was 282 minutes (range, 19 to 1,021 minutes), and mean residence time (MRT) was 360 minutes (range, 19 to 819 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),min,282,98940,DB01136,Carvedilol
,16379664,mean residence time (MRT),"The median peak concentration (extrapolated) of carvedilol after IV administration was 476 ng/mL (range, 203 to 1,920 ng/mL), elimination half-life (t(1/2)) was 282 minutes (range, 19 to 1,021 minutes), and mean residence time (MRT) was 360 minutes (range, 19 to 819 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),min,360,98941,DB01136,Carvedilol
,16379664,Volume of distribution at steady state,"Volume of distribution at steady state was 2.0 L/kg (range, 0.7 to 4.3 L/kg).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),[l] / [kg],2.0,98942,DB01136,Carvedilol
,16379664,peak concentration,"After oral administration of carvedilol, the median peak concentration was 24 microg/mL (range, 9 to 173 microg/mL), time to maximum concentration was 90 minutes (range, 60 to 180 minutes), t(1/2) was 82 minutes (range, 64 to 138 minutes), and MRT was 182 minutes (range, 112 to 254 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),[μg] / [ml],24,98943,DB01136,Carvedilol
,16379664,time to maximum concentration,"After oral administration of carvedilol, the median peak concentration was 24 microg/mL (range, 9 to 173 microg/mL), time to maximum concentration was 90 minutes (range, 60 to 180 minutes), t(1/2) was 82 minutes (range, 64 to 138 minutes), and MRT was 182 minutes (range, 112 to 254 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),min,90,98944,DB01136,Carvedilol
,16379664,t(1/2),"After oral administration of carvedilol, the median peak concentration was 24 microg/mL (range, 9 to 173 microg/mL), time to maximum concentration was 90 minutes (range, 60 to 180 minutes), t(1/2) was 82 minutes (range, 64 to 138 minutes), and MRT was 182 minutes (range, 112 to 254 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),min,82,98945,DB01136,Carvedilol
,16379664,MRT,"After oral administration of carvedilol, the median peak concentration was 24 microg/mL (range, 9 to 173 microg/mL), time to maximum concentration was 90 minutes (range, 60 to 180 minutes), t(1/2) was 82 minutes (range, 64 to 138 minutes), and MRT was 182 minutes (range, 112 to 254 minutes).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),min,182,98946,DB01136,Carvedilol
,16379664,bioavailability,"Median bioavailability after oral administration of carvedilol was 2.1% (range, 0.4% to 54%).",Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16379664/),%,2.1,98947,DB01136,Carvedilol
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],43.1,102014,DB01136,Carvedilol
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],45.9,102015,DB01136,Carvedilol
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],29.0,102016,DB01136,Carvedilol
,28522373,total clearance,"Even though data are limited, it appears that despite inhibition of CYP2C9 due to long-term glibenclamide administration to T2DM patients, overall no differences are observed in the total clearance of carvedilol when compared to healthy subjects (43.1 vs. 45.9L/h for (S)-(-)-carvedilol and 29.0 vs. 33.1L/h for (R)-(+)-carvedilol).",Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28522373/),[l] / [h],33.1,102017,DB01136,Carvedilol
,16079496,oral clearance,"The mean values of oral clearance for R- and S-carvedilol were estimated to be 1.01 and 2.15 l/h/kg, respectively.",Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16079496/),[l] / [h·kg],1.01,104292,DB01136,Carvedilol
,16079496,oral clearance,"The mean values of oral clearance for R- and S-carvedilol were estimated to be 1.01 and 2.15 l/h/kg, respectively.",Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16079496/),[l] / [h·kg],2.15,104293,DB01136,Carvedilol
,17408218,bioavailability,The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration.,Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408218/),%,71,107350,DB01136,Carvedilol
,17408218,bioavailability,The bioavailability studies in rats indicated that the carvedilol transdermal patches provided steady-state plasma concentrations with minimal fluctuations and improved bioavailability of 71% (for F3) and 62% (for F6) in comparison with oral administration.,Transdermal therapeutic system of carvedilol: effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17408218/),%,62,107351,DB01136,Carvedilol
,19545060,t1/2,"The main pharmacokinetic parameters of carvedilol were as follows, t1/2 (4.56 +/- 2.56) h, Cmax (46.29 +/- 21.07) ng x mL(-1), AUC(0-infinity) (173.76 +/- 87.36) ng x mL(-1) x h.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),h,4.56,110466,DB01136,Carvedilol
,19545060,Cmax,"The main pharmacokinetic parameters of carvedilol were as follows, t1/2 (4.56 +/- 2.56) h, Cmax (46.29 +/- 21.07) ng x mL(-1), AUC(0-infinity) (173.76 +/- 87.36) ng x mL(-1) x h.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),[ng] / [ml],46.29,110467,DB01136,Carvedilol
,19545060,AUC(0-infinity),"The main pharmacokinetic parameters of carvedilol were as follows, t1/2 (4.56 +/- 2.56) h, Cmax (46.29 +/- 21.07) ng x mL(-1), AUC(0-infinity) (173.76 +/- 87.36) ng x mL(-1) x h.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),[h·ng] / [ml],173.76,110468,DB01136,Carvedilol
,19545060,Kin,"The estimated Kin was (0.41 +/- 0.31)% h(-1), Kout was (0.40 +/- 0.26) h(-1), the IC50 value was (24.40 +/- 21.10) ng x mL(-1) and the area under the effect curve (AUE) was (3.82 +/- 1.46)% h for the indirect response PD model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),[%] / [h],0.41,110469,DB01136,Carvedilol
,19545060,Kout,"The estimated Kin was (0.41 +/- 0.31)% h(-1), Kout was (0.40 +/- 0.26) h(-1), the IC50 value was (24.40 +/- 21.10) ng x mL(-1) and the area under the effect curve (AUE) was (3.82 +/- 1.46)% h for the indirect response PD model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),1/[h],0.40,110470,DB01136,Carvedilol
,19545060,IC50,"The estimated Kin was (0.41 +/- 0.31)% h(-1), Kout was (0.40 +/- 0.26) h(-1), the IC50 value was (24.40 +/- 21.10) ng x mL(-1) and the area under the effect curve (AUE) was (3.82 +/- 1.46)% h for the indirect response PD model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),[ng] / [ml],24.40,110471,DB01136,Carvedilol
,19545060,area under the effect curve (AUE),"The estimated Kin was (0.41 +/- 0.31)% h(-1), Kout was (0.40 +/- 0.26) h(-1), the IC50 value was (24.40 +/- 21.10) ng x mL(-1) and the area under the effect curve (AUE) was (3.82 +/- 1.46)% h for the indirect response PD model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),%·h,3.82,110472,DB01136,Carvedilol
,19545060,Ke0,"The Ke0 was (0.35 +/- 0.27) h(-1), the EC50 was (24.30 +/- 24.30) ng x mL(-1), and the AUE was (5.65 +/- 2.54)% h for the effect-compartment model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),1/[h],0.35,110473,DB01136,Carvedilol
,19545060,EC50,"The Ke0 was (0.35 +/- 0.27) h(-1), the EC50 was (24.30 +/- 24.30) ng x mL(-1), and the AUE was (5.65 +/- 2.54)% h for the effect-compartment model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),[ng] / [ml],24.30,110474,DB01136,Carvedilol
,19545060,AUE,"The Ke0 was (0.35 +/- 0.27) h(-1), the EC50 was (24.30 +/- 24.30) ng x mL(-1), and the AUE was (5.65 +/- 2.54)% h for the effect-compartment model.",Comparison of different pharmacodynamic models for pharmacokinetic-pharmacodynamic (PK-PD) modeling of carvedilol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19545060/),%·h,5.65,110475,DB01136,Carvedilol
,23255198,absolute bioavailability,In vivo pharmacokinetic study revealed that the absolute bioavailability of in situ nasal spray formulation (69.38%) was significantly increased as compared to orally administered CRV (25.96%) with mean residence time 8.65 h.,"Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23255198/),%,69.38,119639,DB01136,Carvedilol
,23255198,absolute bioavailability,In vivo pharmacokinetic study revealed that the absolute bioavailability of in situ nasal spray formulation (69.38%) was significantly increased as compared to orally administered CRV (25.96%) with mean residence time 8.65 h.,"Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23255198/),%,25.96,119640,DB01136,Carvedilol
,23255198,mean residence time,In vivo pharmacokinetic study revealed that the absolute bioavailability of in situ nasal spray formulation (69.38%) was significantly increased as compared to orally administered CRV (25.96%) with mean residence time 8.65 h.,"Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23255198/),h,8.65,119641,DB01136,Carvedilol
,1317234,receptor occupancy,"In the alpha 1-radioreceptor assay, plasma concentrations from 0.9- to 1.7-fold the equilibrium dissociation constant (Ki) of carvedilol could be evaluated 1 as well as 3.5 h after medication, corresponding with a receptor occupancy of 44%-63%.",Oral administration of carvedilol and prazosin inhibits the prostaglandin F2 alpha- and noradrenaline-induced contraction of human hand veins in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1317234/),%,44,125985,DB01136,Carvedilol
,18614419,oral bioavailability,Its oral bioavailability is 25-35% because of first pass metabolism.,Design and in vivo evaluation of carvedilol buccal mucoadhesive patches. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614419/),%,25-35,136384,DB01136,Carvedilol
,18614419,drug release,Patches exhibited drug release in the range of 86.26 to 98.32% in 90 min.,Design and in vivo evaluation of carvedilol buccal mucoadhesive patches. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18614419/),%,86.26 to 98.32,136385,DB01136,Carvedilol
,16767433,AUC(0-16h),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[h·ng] / [ml],24.1,136441,DB01136,Carvedilol
,16767433,AUC(0-16h),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[h·ng] / [ml],15.4,136442,DB01136,Carvedilol
,16767433,C(max),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[ng] / [ml],2.2,136443,DB01136,Carvedilol
,16767433,C(max),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[ng] / [ml],1.6,136444,DB01136,Carvedilol
,16767433,t(max),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),h,2.4,136445,DB01136,Carvedilol
,16767433,t(max),"In the male group, carvedilol led to statistically significant increases in the area under the concentration time curve to 16 h (AUC(0-16h)) and the peak concentration (C(max)) for digoxin, with no change in time to peak (t(max))(AUC(0-16h)= 24.1+/-9.2 ng.h/ml vs. 15.4+/-5.8 ng.h/ml, p<0.001, C(max)=2.2+/-1.0 ng/ml vs. 1.6+/-0.6 ng/ml, p<0.01, t(max)=2.4+/-2.2 h vs. 2.1+/-1.0 h, p>0.05).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),h,2.1,136446,DB01136,Carvedilol
,16767433,AUC(0-16h),"In the male group, carvedilol resulted in a significant increase in the AUC(0-16h) and C(max) for digoxin compared with the female group (AUC(0-16h)=24.1+/- 9.2ng.h/ml vs. 17.0+/-6.8 ng.h/ml, C(max)=2.2+/-1.0 ng/ml vs. 1.5+/-0.6 ng/ml, p<0.05, respectively).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[h·ng] / [ml],24.1,136447,DB01136,Carvedilol
,16767433,AUC(0-16h),"In the male group, carvedilol resulted in a significant increase in the AUC(0-16h) and C(max) for digoxin compared with the female group (AUC(0-16h)=24.1+/- 9.2ng.h/ml vs. 17.0+/-6.8 ng.h/ml, C(max)=2.2+/-1.0 ng/ml vs. 1.5+/-0.6 ng/ml, p<0.05, respectively).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[h·ng] / [ml],17.0,136448,DB01136,Carvedilol
,16767433,C(max),"In the male group, carvedilol resulted in a significant increase in the AUC(0-16h) and C(max) for digoxin compared with the female group (AUC(0-16h)=24.1+/- 9.2ng.h/ml vs. 17.0+/-6.8 ng.h/ml, C(max)=2.2+/-1.0 ng/ml vs. 1.5+/-0.6 ng/ml, p<0.05, respectively).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[ng] / [ml],2.2,136449,DB01136,Carvedilol
,16767433,C(max),"In the male group, carvedilol resulted in a significant increase in the AUC(0-16h) and C(max) for digoxin compared with the female group (AUC(0-16h)=24.1+/- 9.2ng.h/ml vs. 17.0+/-6.8 ng.h/ml, C(max)=2.2+/-1.0 ng/ml vs. 1.5+/-0.6 ng/ml, p<0.05, respectively).",Influence of carvedilol on serum digoxin levels in heart failure: is there any gender difference? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16767433/),[ng] / [ml],1.5,136450,DB01136,Carvedilol
,20705902,AUC ratio,"R/S AUC ratio increased significantly, from approximately 2.3 to 3.0.",The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705902/),,2.3,137471,DB01136,Carvedilol
,20705902,AUC ratio,"R/S AUC ratio increased significantly, from approximately 2.3 to 3.0.",The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20705902/),,3.0,137472,DB01136,Carvedilol
>,22709607,recoveries,Assay recoveries were high (>76%) and internal standard normalized matrix effects were minimal.,A validated enantioselective LC-MS/MS assay for the simultaneous determination of carvedilol and its pharmacologically active 4'-hydroxyphenyl metabolite in human plasma: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22709607/),%,76,140552,DB01136,Carvedilol
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],72,144652,DB01136,Carvedilol
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],156,144653,DB01136,Carvedilol
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],68,144654,DB01136,Carvedilol
,23739952,portal clearance,"The mean (±S.E.) portal clearance value of R- and S-carvedilol in control rats was 72 ± 16 and 156 ± 31 ml/min/kg, respectively, whereas that of the R- and S-enantiomers in hypoxic rats was 68 ± 8 and 113 ± 14 ml/min/kg, respectively.",Effect of chronic hypoxic hypoxia on oxidation and glucuronidation of carvedilol in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23739952/),[ml] / [kg·min],113,144655,DB01136,Carvedilol
,32988361,bioavaila,The hypothesis is to augment the bioavailability and therapeutic potential of low bioavailable Carvedilol (25-35%) through Nanostructured Lipid Carrier (NLC) loaded Transdermal patch (Nanolipid Transferosomes).,Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),%,25-35,149492,DB01136,Carvedilol
,32988361,z,"NLC (C16) was selected as the best formulation based on desirable, less particle size (201.1 ± 2.02 nm), more zeta potential (-37.2 ± 1.84mV) and maximum entrapment efficiency (87.54 ± 1.84%).",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),m,37.2,149493,DB01136,Carvedilol
,32988361,maximum time of peak plasma concentration (Tmax),"It was observed that there was a significant change with p<0.05 among the pharmacokinetic factors of conventional Carvedilol formulation, Carvedilol NLC and Carvedilol NLC loaded Transdermal patch with a maximum time of peak plasma concentration (Tmax) of 4 hrs, 8 hrs and 8 hrs; maximum peak plasma concentration (Cmax) of 0.258 μg/ml, 0.208 μg/ml and 0.108 μg/ml.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),h,4,149494,DB01136,Carvedilol
,32988361,maximum time of peak plasma concentration (Tmax),"It was observed that there was a significant change with p<0.05 among the pharmacokinetic factors of conventional Carvedilol formulation, Carvedilol NLC and Carvedilol NLC loaded Transdermal patch with a maximum time of peak plasma concentration (Tmax) of 4 hrs, 8 hrs and 8 hrs; maximum peak plasma concentration (Cmax) of 0.258 μg/ml, 0.208 μg/ml and 0.108 μg/ml.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),h,8,149495,DB01136,Carvedilol
,32988361,maximum peak plasma concentration (Cmax),"It was observed that there was a significant change with p<0.05 among the pharmacokinetic factors of conventional Carvedilol formulation, Carvedilol NLC and Carvedilol NLC loaded Transdermal patch with a maximum time of peak plasma concentration (Tmax) of 4 hrs, 8 hrs and 8 hrs; maximum peak plasma concentration (Cmax) of 0.258 μg/ml, 0.208 μg/ml and 0.108 μg/ml.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [ml],0.258,149496,DB01136,Carvedilol
,32988361,maximum peak plasma concentration (Cmax),"It was observed that there was a significant change with p<0.05 among the pharmacokinetic factors of conventional Carvedilol formulation, Carvedilol NLC and Carvedilol NLC loaded Transdermal patch with a maximum time of peak plasma concentration (Tmax) of 4 hrs, 8 hrs and 8 hrs; maximum peak plasma concentration (Cmax) of 0.258 μg/ml, 0.208 μg/ml and 0.108 μg/ml.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [ml],0.208,149497,DB01136,Carvedilol
,32988361,maximum peak plasma concentration (Cmax),"It was observed that there was a significant change with p<0.05 among the pharmacokinetic factors of conventional Carvedilol formulation, Carvedilol NLC and Carvedilol NLC loaded Transdermal patch with a maximum time of peak plasma concentration (Tmax) of 4 hrs, 8 hrs and 8 hrs; maximum peak plasma concentration (Cmax) of 0.258 μg/ml, 0.208 μg/ml and 0.108 μg/ml.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [ml],0.108,149498,DB01136,Carvedilol
,32988361,Area Under Curve (AUC0-α),"Area Under Curve (AUC0-α) was established to be 125.127 μg/ml/h, 132.576 μg/ml.h and 841.032 μg/ml.h.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [h·ml],125.127,149499,DB01136,Carvedilol
,32988361,Area Under Curve (AUC0-α),"Area Under Curve (AUC0-α) was established to be 125.127 μg/ml/h, 132.576 μg/ml.h and 841.032 μg/ml.h.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [h·ml],132.576,149500,DB01136,Carvedilol
,32988361,Area Under Curve (AUC0-α),"Area Under Curve (AUC0-α) was established to be 125.127 μg/ml/h, 132.576 μg/ml.h and 841.032 μg/ml.h.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),[μg] / [h·ml],841.032,149501,DB01136,Carvedilol
,32988361,Mean Residence Time (MRT0- α),"Mean Residence Time (MRT0- α) of the drug was established to be 17 hrs, 19 hrs and 82 hrs, respectively.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),h,17,149502,DB01136,Carvedilol
,32988361,Mean Residence Time (MRT0- α),"Mean Residence Time (MRT0- α) of the drug was established to be 17 hrs, 19 hrs and 82 hrs, respectively.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),h,19,149503,DB01136,Carvedilol
,32988361,Mean Residence Time (MRT0- α),"Mean Residence Time (MRT0- α) of the drug was established to be 17 hrs, 19 hrs and 82 hrs, respectively.",Application of Statistical Tooling Techniques for Designing of Carvedilol Nanolipid Transferosomes and its Dermatopharmacokinetic and Pharmacodynamic Studies. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32988361/),h,82,149504,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.9,152383,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],10.4,152384,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],11.9,152385,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],2.4,152386,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.3,152387,DB01136,Carvedilol
,28114735,AUC,"However, the AUC values of the DMC enantiomers were lower in the type 2 diabetes mellitus patients than in the healthy volunteers (DDI and no DDI) [(R)-(+), 6.9, 10.4, 11.9 ng·h/mL; and (S)-(-), 2.4, 4.3, 4.0 ng·h/mL, respectively].",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.0,152388,DB01136,Carvedilol
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],13.9,152389,DB01136,Carvedilol
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],6.6,152390,DB01136,Carvedilol
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],4.9,152391,DB01136,Carvedilol
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],7.2,152392,DB01136,Carvedilol
,28114735,AUC,"In contrast, the AUC values of the OHC enantiomers were higher in the type 2 diabetes mellitus patients [(R)-(+), 13.9, 6.6, 4.9 ng·h/mL; and (S)-(-), 7.2, 1.5, 1.5 ng·h/mL], which explains the fact that the carvedilol pharmacokinetics was unchanged.",Effects of Type 2 Diabetes Mellitus in Patients on Treatment With Glibenclamide and Metformin on Carvedilol Enantiomers Metabolism. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28114735/),[h·ng] / [ml],1.5,152393,DB01136,Carvedilol
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],522,153234,DB01136,Carvedilol
,11225566,AUC0-12,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],927,153235,DB01136,Carvedilol
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],244,153236,DB01136,Carvedilol
,11225566,AUC,"Compared to placebo, fluoxetine coadministration resulted in a 77% increase in mean (+/- SD) R(+) enantiomer AUC0-12 (522 +/- 413 vs. 927 +/- 506 ng.h/mL, p = 0.01) and a nonsignificant increase in S(-) enantiomer AUC (244 +/- 185 vs. 330 +/- 179 ng.h/mL, p = 0.17).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[h·ng] / [ml],330,153237,DB01136,Carvedilol
,11225566,apparent oral clearance,Mean apparent oral clearance for both enantiomers decreased significantly with fluoxetine administration (R(+): 10.3 +/- 7.2 vs.,"Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),,10.3,153238,DB01136,Carvedilol
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],22.5,153239,DB01136,Carvedilol
,11225566,S(-),"4.5 +/- 2.2 mL/min/kg; S(-): 22.5 +/- 12.3 vs. 12.6 +/- 7.4 mL/min/kg; p = 0.004 and 0.03, respectively).","Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11225566/),[ml] / [kg·min],12.6,153240,DB01136,Carvedilol
,2454375,absolute bioavailability,The absolute bioavailability reaches 24% probably due to a first-pass effect.,Pharmacokinetics and disposition of carvedilol in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),%,24,158730,DB01136,Carvedilol
,2454375,maximum concentrations,"After a 50 mg oral dose, maximum concentrations of 66 micrograms/l are achieved within 1.2 h.",Pharmacokinetics and disposition of carvedilol in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),[μg] / [l],66,158731,DB01136,Carvedilol
,2454375,Vz,"C is extensively distributed to the tissues (Vz = 132 l) and eliminated primarily by hepatic metabolism (total clearance 590 ml/min, renal clearance 4 ml/min).",Pharmacokinetics and disposition of carvedilol in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),l,132,158732,DB01136,Carvedilol
,2454375,total clearance,"C is extensively distributed to the tissues (Vz = 132 l) and eliminated primarily by hepatic metabolism (total clearance 590 ml/min, renal clearance 4 ml/min).",Pharmacokinetics and disposition of carvedilol in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),[ml] / [min],590,158733,DB01136,Carvedilol
,2454375,renal clearance,"C is extensively distributed to the tissues (Vz = 132 l) and eliminated primarily by hepatic metabolism (total clearance 590 ml/min, renal clearance 4 ml/min).",Pharmacokinetics and disposition of carvedilol in humans. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),[ml] / [min],4,158734,DB01136,Carvedilol
,2454375,half-life,"Because of the longer half-life of 6.4 h after oral administration in contrast to 2.4 h after i.v. administration, C is assumed to be absorption dependent since no sustained-release formulation was used.",Pharmacokinetics and disposition of carvedilol in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),h,6.4,158735,DB01136,Carvedilol
,2454375,half-life,"Because of the longer half-life of 6.4 h after oral administration in contrast to 2.4 h after i.v. administration, C is assumed to be absorption dependent since no sustained-release formulation was used.",Pharmacokinetics and disposition of carvedilol in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),h,2.4,158736,DB01136,Carvedilol
,2454375,half-life of radioactivity,The half-life of radioactivity in plasma is 39 h; 16% of C is excreted in urine in the form of metabolites and only 0.3% unchanged.,Pharmacokinetics and disposition of carvedilol in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454375/),h,39,158737,DB01136,Carvedilol
,3428345,Cmax,For the 50 mg capsule Cmax was 66 micrograms.,"Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),μg,66,162174,DB01136,Carvedilol
,3428345,tmax,"l-1, tmax 1.2 h, t1/2 6.4 h.","Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),h,1.2,162175,DB01136,Carvedilol
,3428345,t1/2,"l-1, tmax 1.2 h, t1/2 6.4 h.","Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),h,6.4,162176,DB01136,Carvedilol
,3428345,t1/2,"The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and VZ 132 l.","Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),h,2.4,162177,DB01136,Carvedilol
,3428345,CL,"The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and VZ 132 l.","Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),[ml] / [min],589,162178,DB01136,Carvedilol
,3428345,VZ,"The t1/2 after i.v. administration was 2.4 h, CL 589 ml/min and VZ 132 l.","Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),l,132,162179,DB01136,Carvedilol
,3428345,absolute bioavailability,The absolute bioavailability was 24% (50 mg capsule).,"Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3428345/),%,24,162180,DB01136,Carvedilol
,23728853,CL,"The typical mean value for carvedilol CL, estimated by the base model, in the target population was 43.8 L/h.",Population pharmacokinetics of carvedilol in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23728853/),[l] / [h],43.8,166248,DB01136,Carvedilol
,18451529,CL/F,"On the other hand, the mean CL/F values of R- and S-carvedilol in patients with heart failure were 0.89 and 1.52 l/h/kg, respectively, considerably lower than those estimated previously in healthy subjects.",Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451529/),[l] / [h·kg],0.89,187805,DB01136,Carvedilol
,18451529,CL/F,"On the other hand, the mean CL/F values of R- and S-carvedilol in patients with heart failure were 0.89 and 1.52 l/h/kg, respectively, considerably lower than those estimated previously in healthy subjects.",Pharmacokinetics of R- and S-carvedilol in routinely treated Japanese patients with heart failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18451529/),[l] / [h·kg],1.52,187806,DB01136,Carvedilol
,17023231,time to maximum observed plasma concentration (t(max)),The median time to maximum observed plasma concentration (t(max)) was approximately 3 hours longer for both enantiomers after administration of carvedilol CR as compared with carvedilol IR.,Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17023231/),h,3,187896,DB01136,Carvedilol
,23483571,recovery,The assay recovery was within 94-99% for both the analytes and IS.,UPLC-MS/MS assay for the simultaneous quantification of carvedilol and its active metabolite 4'-hydroxyphenyl carvedilol in human plasma to support a bioequivalence study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23483571/),%,94-99,188013,DB01136,Carvedilol
,22113887,nasal bioavailability,The nasal bioavailability was 67.87% which indicates that nasal administration results in improved absorption of CRV.,In vivo evaluation of alginate microspheres of carvedilol for nasal delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22113887/),%,67.87,189176,DB01136,Carvedilol
,23447077,Cmax,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [ml],73.71,195411,DB01136,Carvedilol
,23447077,AUC0-24,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [ml],78.93,195412,DB01136,Carvedilol
,23447077,AUC0-24,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [h·ml],285.1,195413,DB01136,Carvedilol
,23447077,AUC0-∞,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [h·ml],296.9,195414,DB01136,Carvedilol
,23447077,AUC0-∞,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [h·ml],296.5,195415,DB01136,Carvedilol
,23447077,AUC0-∞,"The mean (SD) Cmax, AUC0-24, and AUC0-∞ values after administration of the test and reference formulations, respectively, were as follows: 73.71 (34.04) vs. 78.93 (43.64) ng/mL, 285.1 (147.0) vs. 296.9 (176.1) ng/mL · h, and 296.5 (161.4) vs. 303.4 (177.9) ng/mL · h.","Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),[ng] / [h·ml],303.4,195416,DB01136,Carvedilol
,23447077,relative bioavailability,The relative bioavailability of the test formulation to reference formulation was 100.1%.,"Bioequivalence and pharmacokinetic evaluation of two tablet formulations of carvedilol 25-mg: a single-dose, randomized-sequence, open-label, two-way crossover study in healthy Chinese male volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23447077/),%,100.1,195417,DB01136,Carvedilol
,25176381,AUC,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[h·βg] / [ml],0.076,195869,DB01136,Carvedilol
,25176381,AUC,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[h·βg] / [ml],0.197,195870,DB01136,Carvedilol
,25176381,Cmax,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[h·βg] / [ml],0.076,195871,DB01136,Carvedilol
,25176381,Cmax,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[βg] / [ml],0.024,195872,DB01136,Carvedilol
,25176381,Cmax,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[h·βg] / [ml],0.197,195873,DB01136,Carvedilol
,25176381,Cmax,"Mean (SD) values of AUC and Cmax 0.076±0.021βg.h/ml and 0.024±0.005βg/mL, respectively) in male differ significantly (P<0.05) from the female 0.197±0.042βg.h/ml and 0.048±0.02βg/mL, respectively).",Assessment of sex differences in Pharmacokinetics of carvedilol in human. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176381/),[βg] / [ml],0.048,195874,DB01136,Carvedilol
,19046015,area under the concentration-time curve extrapolated to infinity (AUCinf),"After oral administration of bisoprolol, the geometric mean value of the area under the concentration-time curve extrapolated to infinity (AUCinf) was 2,195 microg/L (coefficient of variation [CV], 15%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],"2,195",197509,DB01136,Carvedilol
,19046015,AUCinf,"After IV administration of bisoprolol, the dose-normalized geometric mean AUCinf was 2,402 microg/L (CV, 19%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],"2,402",197510,DB01136,Carvedilol
,19046015,Oral bioavailability,Oral bioavailability of bisoprolol was 91.4%.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),%,91.4,197511,DB01136,Carvedilol
,19046015,AUCinf,"After oral administration of carvedilol, the geometric mean AUCinf was 70 microg/L (CV, 81%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],70,197512,DB01136,Carvedilol
,19046015,AUCinf,"After IV administration of carvedilol, the geometric mean AUCinf was 491 microg/L (CV, 23%).",Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[μg] / [l],491,197513,DB01136,Carvedilol
,19046015,Oral bioavailability,Oral bioavailability of carvedilol was 14.3%.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),%,14.3,197514,DB01136,Carvedilol
,19046015,Total body clearance,Total body clearance was low (0.42 L/h/kg) for bisoprolol and high (2.0 L/h/kg) for carvedilol.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[l] / [h·kg],0.42,197515,DB01136,Carvedilol
,19046015,Total body clearance,Total body clearance was low (0.42 L/h/kg) for bisoprolol and high (2.0 L/h/kg) for carvedilol.,Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19046015/),[l] / [h·kg],2.0,197516,DB01136,Carvedilol
,18551504,AUC(SS) (0-12),The data obtained demonstrated highest plasma levels for the R(+)-carvedilol (AUC(SS) (0-12) 75.64 vs 37.29 ng/ml).,Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551504/),[ng] / [ml],75.64,199480,DB01136,Carvedilol
,18551504,AUC(SS) (0-12),The data obtained demonstrated highest plasma levels for the R(+)-carvedilol (AUC(SS) (0-12) 75.64 vs 37.29 ng/ml).,Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551504/),[ng] / [ml],37.29,199481,DB01136,Carvedilol
,18551504,Ae(0-12),The enantiomeric ratio R(+)/S(-) was 2.03 for plasma and 1.49 for urine (Ae(0-12) 17.4 vs 11.7 microg).,Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551504/),μg,17.4,199482,DB01136,Carvedilol
,18551504,Ae(0-12),The enantiomeric ratio R(+)/S(-) was 2.03 for plasma and 1.49 for urine (Ae(0-12) 17.4 vs 11.7 microg).,Stereoselective analysis of carvedilol in human plasma and urine using HPLC after chiral derivatization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18551504/),μg,11.7,199483,DB01136,Carvedilol
,23850816,bioavailability,The results showed that the bioavailability of CAR was improved 179.3% compared with that of the commercial product when c-MCM was used as the drug carrier.,Carboxylated mesoporous carbon microparticles as new approach to improve the oral bioavailability of poorly water-soluble carvedilol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23850816/),%,179.3,204621,DB01136,Carvedilol
,17457833,limit of detection,The limit of detection in the MRM mode was found to be 1.25 ng/ml.,Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),[ng] / [ml],1.25,205643,DB01136,Carvedilol
,17457833,terminal half-lives,"The terminal half-lives of (+)-(R)-2F109 and (-)-(S)-2F109 were 33.5 and 42.6 min, respectively.",Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),min,33.5,205644,DB01136,Carvedilol
,17457833,terminal half-lives,"The terminal half-lives of (+)-(R)-2F109 and (-)-(S)-2F109 were 33.5 and 42.6 min, respectively.",Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457833/),min,42.6,205645,DB01136,Carvedilol
,19255893,AUC(0-t),"As indicated by pharmacokinetic data, the AUC(0-t) of all three (SLN) formulations (6.27 +/- 0.24 microgh/mL with FZ-1, 4.13 +/- 0.11 microgh/mL with FZ-2, and 3.63 +/- 0.10 microgh/mL with FZ-3) were significantly higher (p < 0.05) than that of carvedilol suspension (1.27 +/- 0.23 microgh/mL).",Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19255893/),[μgh] / [ml],6.27,208182,DB01136,Carvedilol
,19255893,AUC(0-t),"As indicated by pharmacokinetic data, the AUC(0-t) of all three (SLN) formulations (6.27 +/- 0.24 microgh/mL with FZ-1, 4.13 +/- 0.11 microgh/mL with FZ-2, and 3.63 +/- 0.10 microgh/mL with FZ-3) were significantly higher (p < 0.05) than that of carvedilol suspension (1.27 +/- 0.23 microgh/mL).",Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19255893/),[μgh] / [ml],4.13,208183,DB01136,Carvedilol
,19255893,AUC(0-t),"As indicated by pharmacokinetic data, the AUC(0-t) of all three (SLN) formulations (6.27 +/- 0.24 microgh/mL with FZ-1, 4.13 +/- 0.11 microgh/mL with FZ-2, and 3.63 +/- 0.10 microgh/mL with FZ-3) were significantly higher (p < 0.05) than that of carvedilol suspension (1.27 +/- 0.23 microgh/mL).",Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19255893/),[μgh] / [ml],3.63,208184,DB01136,Carvedilol
,19255893,AUC(0-t),"As indicated by pharmacokinetic data, the AUC(0-t) of all three (SLN) formulations (6.27 +/- 0.24 microgh/mL with FZ-1, 4.13 +/- 0.11 microgh/mL with FZ-2, and 3.63 +/- 0.10 microgh/mL with FZ-3) were significantly higher (p < 0.05) than that of carvedilol suspension (1.27 +/- 0.23 microgh/mL).",Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19255893/),[μgh] / [ml],1.27,208185,DB01136,Carvedilol
,3559930,Vdss,"Carvedilol serum concentration-time profiles were fitted best to a three-compartment model and the pharmacokinetic data revealed the following mean values: Vdss of 1.97 L/kg, mean residence time (MRT) of 4.66 h, and CL of 0.437 L X h-1 X kg-1.",Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559930/),[l] / [kg],1.97,208480,DB01136,Carvedilol
,3559930,mean residence time (MRT),"Carvedilol serum concentration-time profiles were fitted best to a three-compartment model and the pharmacokinetic data revealed the following mean values: Vdss of 1.97 L/kg, mean residence time (MRT) of 4.66 h, and CL of 0.437 L X h-1 X kg-1.",Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559930/),h,4.66,208481,DB01136,Carvedilol
,3559930,CL,"Carvedilol serum concentration-time profiles were fitted best to a three-compartment model and the pharmacokinetic data revealed the following mean values: Vdss of 1.97 L/kg, mean residence time (MRT) of 4.66 h, and CL of 0.437 L X h-1 X kg-1.",Liquid chromatographic assay and disposition of carvedilol in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3559930/),[l] / [h·kg],0.437,208482,DB01136,Carvedilol
,22047549,maximum mucoadhesive force,"Optimized formulation, CMT1 (CMT, chitosan microsphere tablet) showed maximum mucoadhesive force (50 ± 1.84 dyne/cm²), exhibited 73.08 ± 3.05% drug release and demonstrated zero-order kinetics with non-Fickian release mechanism.","Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22047549/),[dyne] / [cm²],50,208636,DB01136,Carvedilol
,22047549,C(max),"Pharmacokinetic studies in rabbits showed significantly higher C(max) (71.26 ± 6.45 ng/mL), AUC(0-10) (AUC, area under the curve 390.75 ± 5.23 ng/mL/h) and AUC(0-∞) (664.72 ng/mL/h) than carvedilol oral tablet.","Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22047549/),[ng] / [ml],71.26,208637,DB01136,Carvedilol
,22047549,"AUC(0-10) (AUC, area under the curve","Pharmacokinetic studies in rabbits showed significantly higher C(max) (71.26 ± 6.45 ng/mL), AUC(0-10) (AUC, area under the curve 390.75 ± 5.23 ng/mL/h) and AUC(0-∞) (664.72 ng/mL/h) than carvedilol oral tablet.","Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22047549/),[ng] / [h·ml],390.75,208638,DB01136,Carvedilol
,22047549,AUC(0-∞),"Pharmacokinetic studies in rabbits showed significantly higher C(max) (71.26 ± 6.45 ng/mL), AUC(0-10) (AUC, area under the curve 390.75 ± 5.23 ng/mL/h) and AUC(0-∞) (664.72 ng/mL/h) than carvedilol oral tablet.","Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22047549/),[ng] / [h·ml],664.72,208639,DB01136,Carvedilol
,15473670,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 48.9 and 21.6 ng/mL for (R)-carvedilol and (S)-carvedilol, respectively, determined by the chiral method.",Enantioselective pharmacokinetics of carvedilol in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473670/),[ng] / [ml],48.9,209024,DB01136,Carvedilol
,15473670,maximum plasma concentrations (Cmax),"The maximum plasma concentrations (Cmax) were 48.9 and 21.6 ng/mL for (R)-carvedilol and (S)-carvedilol, respectively, determined by the chiral method.",Enantioselective pharmacokinetics of carvedilol in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473670/),[ng] / [ml],21.6,209025,DB01136,Carvedilol
,15473670,Cmax,"The profiles of the plasma concentration of (RS)-carvedilol showed Cmax of 71.5, 72.2, and 73.5 ng/mL, as determined by the CE, HPLC/FD methods and calculations from the data of the chiral method, respectively.",Enantioselective pharmacokinetics of carvedilol in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473670/),[ng] / [ml],71.5,209026,DB01136,Carvedilol
,15473670,Cmax,"The profiles of the plasma concentration of (RS)-carvedilol showed Cmax of 71.5, 72.2, and 73.5 ng/mL, as determined by the CE, HPLC/FD methods and calculations from the data of the chiral method, respectively.",Enantioselective pharmacokinetics of carvedilol in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473670/),[ng] / [ml],72.2,209027,DB01136,Carvedilol
,15473670,Cmax,"The profiles of the plasma concentration of (RS)-carvedilol showed Cmax of 71.5, 72.2, and 73.5 ng/mL, as determined by the CE, HPLC/FD methods and calculations from the data of the chiral method, respectively.",Enantioselective pharmacokinetics of carvedilol in human volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15473670/),[ng] / [ml],73.5,209028,DB01136,Carvedilol
,17702675,recovery,The accuracy ranges from 87.3 to 100.88% and the recovery of carvedilol was 69.90%.,Estimation of carvedilol in human plasma by using HPLC-fluorescence detector and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17702675/),%,69.90,213775,DB01136,Carvedilol
,26546947,absolute bioavailability,Carvedilol (CVD) suffers from low absolute bioavailability (25%) due to its limited aqueous solubility and hepatic first-pass metabolism.,Laminated sponges as challenging solid hydrophilic matrices for the buccal delivery of carvedilol microemulsion systems: Development and proof of concept via mucoadhesion and pharmacokinetic assessments in healthy human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26546947/),%,25,217955,DB01136,Carvedilol
,22271587,quantification limit,The quantification limit was 0.2 ng ml(-1) for both enantiomers in plasma.,Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271587/),[ng] / [ml],0.2,221107,DB01136,Carvedilol
,22271587,AUC(0-∞),The results showed a higher plasma concentration of (+)-(R)-carvedilol (AUC(0-∞) 205.52 vs.,Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22271587/),,205.52,221108,DB01136,Carvedilol
,31128197,drug entrapment efficiency,The optimized formulation showed particle size 102.12 nm and drug entrapment efficiency 71.26 ± 1.16%.,Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31128197/),%,71.26,222429,DB01136,Carvedilol
,2454376,bioavailability,Carvedilol was absorbed rapidly after oral administration with a bioavailability of approximately 45% and obeyed linear pharmacokinetics over the dose range 25-50 mg.,A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454376/),%,45,224408,DB01136,Carvedilol
,2454376,terminal elimination half-life,The terminal elimination half-life varied between 5 and 14 h.,A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454376/),h,5 and 14,224409,DB01136,Carvedilol
,27262994,flow rate,"The analytes and the internal standard (diazepam) were separated on an Acquity UPLC BEH C18 chromatography column (2.1mm×50mm, 1.7μm) using gradient elution with a mobile phase of acetonitrile and 0.1% formic acid in water at a flow rate of 0.4mL/min.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),[ml] / [min],0.4,226496,DB01136,Carvedilol
,27262994,m,"The detection was performed on a triple quadrupole tandem mass spectrometer by multiple reaction monitoring (MRM) mode to monitor the precursor-to-product ion transitions of m/z 299.2→150.1 for vortioxetine, m/z 407.2→100.3 for carvedilol, m/z 423.2→100.1 for 4-hydroxyphenyl carvedilol and m/z 285.2→193.1 for diazepam (IS) using a positive electrospray ionization interface.","Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),,423.2,226497,DB01136,Carvedilol
,27262994,Total time,Total time for each chromatograph was 3.0min.,"Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27262994/),min,3.0,226498,DB01136,Carvedilol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],72,234919,DB01136,Carvedilol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],87,234920,DB01136,Carvedilol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],44,234921,DB01136,Carvedilol
,29519953,dialytic clearance,"Using the recovery clearance method, the dialytic clearance values for atenolol, metoprolol, bisoprolol, and carvedilol were 72, 87, 44, and 0.2 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],0.2,234922,DB01136,Carvedilol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],167,234923,DB01136,Carvedilol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],114,234924,DB01136,Carvedilol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],96,234925,DB01136,Carvedilol
,29519953,dialytic clearance,"Applying the arterial venous difference method, the dialytic clearance values of atenolol, metoprolol, bisoprolol, and carvedilol were 167, 114, 96, and 24 ml/min, respectively (P<0.001).",β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29519953/),[ml] / [min],24,234926,DB01136,Carvedilol
,2908306,Trough supine DBP,"Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),hg·mm,0.6,237912,DB01136,Carvedilol
,2908306,Trough supine DBP,"Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),hg·mm,7.3,237913,DB01136,Carvedilol
,2908306,Trough supine DBP,"Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),hg·mm,8.8,237914,DB01136,Carvedilol
,2908306,Trough supine DBP,"Trough supine DBP after 4 weeks of treatment were 0.6 +/- 6.5, 7.3 +/- 7.9, 8.8 +/- 7.4 and 12.1 +/- 3.8mm Hg (+/- SD) below baseline.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),hg·mm,12.1,237915,DB01136,Carvedilol
,2908306,Peak serum levels,"Peak serum levels were 39 +/- 27, 75 +/- 38 and 161 +/- 131 mu/L for carvedilol 12.5, 25 and 50mg.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),[mu] / [l],39,237916,DB01136,Carvedilol
,2908306,Peak serum levels,"Peak serum levels were 39 +/- 27, 75 +/- 38 and 161 +/- 131 mu/L for carvedilol 12.5, 25 and 50mg.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),[mu] / [l],75,237917,DB01136,Carvedilol
,2908306,Peak serum levels,"Peak serum levels were 39 +/- 27, 75 +/- 38 and 161 +/- 131 mu/L for carvedilol 12.5, 25 and 50mg.",Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2908306/),[mu] / [l],161,237918,DB01136,Carvedilol
,25715807,absolute bioavailability,The nanotransfersomal vesicles were significantly more efficient in nasal delivery of carvedilol with absolute bioavailability of 63.4%.,"Nanotransfersomes of carvedilol for intranasal delivery: formulation, characterization and in vivo evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25715807/),%,63.4,238910,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,10.28,238950,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,10.89,238951,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,5.94,238952,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,3.22,238953,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,1.58,238954,DB01136,Carvedilol
,26569478,inhibition ratios,"The inhibition ratios in human liver microsomes were 10.28, 10.89 and 5.94% for 4'-HPC, 5'-HPC and o-DMC, respectively, while in rat liver microsomes, they were 3.22, 1.58 and 1.81%, respectively.",The Effect of Apatinib on the Metabolism of Carvedilol Both in vitro and in vivo. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26569478/),%,1.81,238955,DB01136,Carvedilol
,30616109,surface area,"HMSNs prepared in our current study has exhibited high surface area (886.84 m2/g), pore volume (0.79 cm3/g), and uniform pore size (3.18 nm), which also enabled the greater encapsulation of the model BSC II drug Carvedilol (CAR) inside the HMSNs.",Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30616109/),[m2] / [g],886.84,253334,DB01136,Carvedilol
,30616109,pore volume,"HMSNs prepared in our current study has exhibited high surface area (886.84 m2/g), pore volume (0.79 cm3/g), and uniform pore size (3.18 nm), which also enabled the greater encapsulation of the model BSC II drug Carvedilol (CAR) inside the HMSNs.",Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30616109/),[cm3] / [g],0.79,253335,DB01136,Carvedilol
,30616109,drug loading,This technique also helped in achieving a high drug loading of (40.22 ± 0.73)%.,Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30616109/),%,40.22,253336,DB01136,Carvedilol
,10424319,AUC(0-24h),"Mean with (SD) AUC(0-24h) (ng x h x ml(-1)) for carvedilol was 220 (120) and 618 (335) in CRI compared with 165 (83.5) and 413 (247) in controls on Days 1 and 9, respectively, primarily due to higher R-carvedilol concentrations.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[h·ng] / [ml],220,256122,DB01136,Carvedilol
,10424319,AUC(0-24h),"Mean with (SD) AUC(0-24h) (ng x h x ml(-1)) for carvedilol was 220 (120) and 618 (335) in CRI compared with 165 (83.5) and 413 (247) in controls on Days 1 and 9, respectively, primarily due to higher R-carvedilol concentrations.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[h·ng] / [ml],618,256123,DB01136,Carvedilol
,10424319,AUC(0-24h),"Mean with (SD) AUC(0-24h) (ng x h x ml(-1)) for carvedilol was 220 (120) and 618 (335) in CRI compared with 165 (83.5) and 413 (247) in controls on Days 1 and 9, respectively, primarily due to higher R-carvedilol concentrations.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[h·ng] / [ml],165,256124,DB01136,Carvedilol
,10424319,AUC(0-24h),"Mean with (SD) AUC(0-24h) (ng x h x ml(-1)) for carvedilol was 220 (120) and 618 (335) in CRI compared with 165 (83.5) and 413 (247) in controls on Days 1 and 9, respectively, primarily due to higher R-carvedilol concentrations.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[h·ng] / [ml],413,256125,DB01136,Carvedilol
,10424319,Cmax,"Mean with (SD) Cmax (ng x ml(-1)) for carvedilol were 53.4 (31.4) and 128 (63.3) in CRI compared with 46.7 (23.3) and 104 (58.9) in controls on Days 1 and 9, respectively.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[ng] / [ml],53.4,256126,DB01136,Carvedilol
,10424319,Cmax,"Mean with (SD) Cmax (ng x ml(-1)) for carvedilol were 53.4 (31.4) and 128 (63.3) in CRI compared with 46.7 (23.3) and 104 (58.9) in controls on Days 1 and 9, respectively.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[ng] / [ml],128,256127,DB01136,Carvedilol
,10424319,Cmax,"Mean with (SD) Cmax (ng x ml(-1)) for carvedilol were 53.4 (31.4) and 128 (63.3) in CRI compared with 46.7 (23.3) and 104 (58.9) in controls on Days 1 and 9, respectively.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[ng] / [ml],46.7,256128,DB01136,Carvedilol
,10424319,Cmax,"Mean with (SD) Cmax (ng x ml(-1)) for carvedilol were 53.4 (31.4) and 128 (63.3) in CRI compared with 46.7 (23.3) and 104 (58.9) in controls on Days 1 and 9, respectively.",The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10424319/),[ng] / [ml],104,256129,DB01136,Carvedilol
,17468057,flow rate,"A Synergi Hydro-RP (50 mm x 2 mm i.d.; 4 microm) column was used with acetonitile:water:formic acid mobile phase (32:68:0.01, v/v) at a flow rate of 200 microL/min into a single quadrupole mass spectrometer with an electrospray interface in the positive SIM mode.",Single quadrupole mass spectrometry for pre-clinical pharmacokinetic analysis: quantitation of carvedilol in dog plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17468057/),[μl] / [min],200,256615,DB01136,Carvedilol
,2096213,time to peak fall,The time to peak fall in BP was about 4 hours and was always after the time to peak blood level.,Pharmacokinetics of carvedilol in older and younger patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2096213/),h,4,258070,DB01136,Carvedilol
,1378143,absolute bioavailability,The R(+)-enantiomer has twice (31.1%) the absolute bioavailability than the S(-) form (15.1%).,Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378143/),%,15.1,259384,DB01136,Carvedilol
,1378143,absolute bioavailabilities,"Although the difference between areas under the curve of R(+) and S(-) were of borderline significance after i.v. administration but significant after oral administration, no difference existed between the absolute bioavailabilities of R(+) (83.7%) and S(-) (71.3%).",Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378143/),%,83.7,259385,DB01136,Carvedilol
,1378143,absolute bioavailabilities,"Although the difference between areas under the curve of R(+) and S(-) were of borderline significance after i.v. administration but significant after oral administration, no difference existed between the absolute bioavailabilities of R(+) (83.7%) and S(-) (71.3%).",Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1378143/),%,71.3,259386,DB01136,Carvedilol
,17614362,Oral clearance,Oral clearance of S(-)-carvedilol was 149 L/h.,Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614362/),[l] / [h],149,260610,DB01136,Carvedilol
,17614362,bioavailability (F(rel)),"The IR(PM) and the CR doses had bioavailability (F(rel)) of 0.80 and 0.76, respectively, relative to the IR(AM) dose.",Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614362/),,0.80,260611,DB01136,Carvedilol
,17614362,bioavailability (F(rel)),"The IR(PM) and the CR doses had bioavailability (F(rel)) of 0.80 and 0.76, respectively, relative to the IR(AM) dose.",Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17614362/),,0.76,260612,DB01136,Carvedilol
,1823868,Urinary excretion of,"Urinary excretion of radioactivity amounted to 16% of which 2% represented unchanged drug, 32% carvedilol-glucuronide and about 25% side chain oxidation products.",Metabolism of carvedilol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823868/),%,16,261913,DB01136,Carvedilol
,1823868,Urinary excretion of,"Urinary excretion of radioactivity amounted to 16% of which 2% represented unchanged drug, 32% carvedilol-glucuronide and about 25% side chain oxidation products.",Metabolism of carvedilol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823868/),%,2,261914,DB01136,Carvedilol
,1823868,Urinary excretion of,"Urinary excretion of radioactivity amounted to 16% of which 2% represented unchanged drug, 32% carvedilol-glucuronide and about 25% side chain oxidation products.",Metabolism of carvedilol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823868/),%,32,261915,DB01136,Carvedilol
,1823868,Urinary excretion of,"Urinary excretion of radioactivity amounted to 16% of which 2% represented unchanged drug, 32% carvedilol-glucuronide and about 25% side chain oxidation products.",Metabolism of carvedilol in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1823868/),%,25,261916,DB01136,Carvedilol
,30161251,zeta potential,The results of this study revealed that the CVD-SLNs have a colloidal size of 31.3 nm with zeta potential of 24.25 mV indicating good stability and 91.43% entrapment efficiency.,Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30161251/),mv,24.25,272518,DB01136,Carvedilol
,30161251,mean residence time,The in vivo pharmacokinetics results indicated the prolongation in the mean residence time of CVD to 23 h when delivered in SLNs and its oral bioavailability enhanced by more than 2-folds.,Optimization of carvedilol solid lipid nanoparticles: An approach to control the release and enhance the oral bioavailability on rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30161251/),h,23,272519,DB01136,Carvedilol
